BR112012013780B8 - biorreator para modular linfócitos e suprimir células t autorreativas, sistema para inibição de um distúrbio autoimune, e, método ativar células t reguladoras - Google Patents

biorreator para modular linfócitos e suprimir células t autorreativas, sistema para inibição de um distúrbio autoimune, e, método ativar células t reguladoras

Info

Publication number
BR112012013780B8
BR112012013780B8 BR112012013780A BR112012013780A BR112012013780B8 BR 112012013780 B8 BR112012013780 B8 BR 112012013780B8 BR 112012013780 A BR112012013780 A BR 112012013780A BR 112012013780 A BR112012013780 A BR 112012013780A BR 112012013780 B8 BR112012013780 B8 BR 112012013780B8
Authority
BR
Brazil
Prior art keywords
cells
lymphocytes
bioreactor
inhibiting
stem cells
Prior art date
Application number
BR112012013780A
Other languages
English (en)
Other versions
BR112012013780A2 (pt
BR112012013780B1 (pt
Inventor
Zhao Yong
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of BR112012013780A2 publication Critical patent/BR112012013780A2/pt
Publication of BR112012013780B1 publication Critical patent/BR112012013780B1/pt
Publication of BR112012013780B8 publication Critical patent/BR112012013780B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A61M1/3489—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents by biological cells, e.g. bioreactor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/06—Plates; Walls; Drawers; Multilayer plates
    • C12M25/08—Plates; Walls; Drawers; Multilayer plates electrically charged
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/08—Chemical, biochemical or biological means, e.g. plasma jet, co-culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0405—Lymph
    • A61M2202/0407—Lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Abstract

biorreator para modular os linfócitos e suprimir as células t autorreativas, sistema para inibição de um distúrbio autoimune, e, método ativar as células t reguladoras métodos e aparelhos são descritos co-cultivando células tronco com células mononucleares e/ou linfócitos para modular sua função. a invenção também descreve o uso de células tronco para educar as células imunes auto-reativas como um aparelho para o tratamento de doenças autoimunes e doenças relacionadas com distúrbio imune, tais como diabete. em um aspecto da invenção, biorreatores são descritos para modular linfócitos e suprimir células t autorreativas. os biorreatores podem incluir uma câmara tendo pelo menos uma superfície de substrato positivamente carregado e/ou hidrofóbico, uma população de células tronco ligadas à superfície de substrato, um conduto de entrada para a introdução de linfócitos na câmara e um conduto de saída para extrair os linfócitos tratados seguindo a co-cultura com as células tronco.
BR112012013780A 2009-12-08 2010-12-08 biorreator para modular linfócitos e suprimir células t autorreativas, sistema para inibição de um distúrbio autoimune, e, método ativar células t reguladoras BR112012013780B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28378209P 2009-12-08 2009-12-08
US28381009P 2009-12-08 2009-12-08
US61/283,810 2009-12-08
US61/283,782 2009-12-08
PCT/US2010/059522 WO2011087637A1 (en) 2009-12-08 2010-12-08 Stem cell immune modulation methods of use and apparatus

Publications (3)

Publication Number Publication Date
BR112012013780A2 BR112012013780A2 (pt) 2019-09-24
BR112012013780B1 BR112012013780B1 (pt) 2021-02-17
BR112012013780B8 true BR112012013780B8 (pt) 2021-07-27

Family

ID=44304549

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013780A BR112012013780B8 (pt) 2009-12-08 2010-12-08 biorreator para modular linfócitos e suprimir células t autorreativas, sistema para inibição de um distúrbio autoimune, e, método ativar células t reguladoras

Country Status (12)

Country Link
US (1) US9101726B2 (pt)
EP (1) EP2510084B1 (pt)
JP (1) JP6047403B2 (pt)
KR (1) KR101718773B1 (pt)
CN (1) CN102471753B (pt)
AU (1) AU2010341703B2 (pt)
BR (1) BR112012013780B8 (pt)
CA (1) CA2782757C (pt)
DK (1) DK2510084T3 (pt)
ES (1) ES2784183T3 (pt)
IL (1) IL220290A (pt)
WO (1) WO2011087637A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101358777B1 (ko) * 2013-04-30 2014-02-10 서울대학교병원 심장내막 유래의 성체줄기세포 및 이의 제조방법
US20170239297A1 (en) * 2014-08-18 2017-08-24 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
EP3250682A4 (en) * 2015-01-26 2018-08-01 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
AU2016296741A1 (en) 2015-07-21 2018-02-22 The Children's Medical Center Corporation PD-L1 expressing hematopoietic stem cells and uses
CN105219709A (zh) * 2015-09-23 2016-01-06 上海吉泉生物技术有限公司 单采法建立免疫细胞库及应用
WO2017079674A1 (en) * 2015-11-04 2017-05-11 Northeastern University Systems for producing cellular immunotherapeutics and methods of use thereof
WO2018044914A1 (en) * 2016-08-29 2018-03-08 Hackensack University Medical Center Methods for treating an immune disorder-related disease by reducing autoreactivity in a t cell compartment
IT201600130565A1 (it) * 2016-12-23 2018-06-23 Univ Degli Studi Di Palermo Metodo di co-coltura cellulare in vitro per indurre la tolleranza immunologica
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
US10647954B1 (en) 2018-11-15 2020-05-12 Flaskworks, Llc Dendritic cell generating apparatus and method
KR102232757B1 (ko) * 2018-11-22 2021-03-26 (주)엑솔런스바이오테크놀로지 체외충격파를 이용한 표적물질 전달 장치
DE102019106651A1 (de) * 2019-03-15 2020-09-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Behandlungsvorrichtung und -verfahren zur extrakorporalen, Immuntoleranz-steigernden Blutbehandlung
US11566217B2 (en) 2019-08-13 2023-01-31 Flaskworks, Llc Duty cycle for cell culture systems
CN110592012A (zh) * 2019-09-29 2019-12-20 杭州电子科技大学 一种增强抗肿瘤免疫活性的免疫细胞的制备方法及其应用
KR20220086625A (ko) 2019-10-21 2022-06-23 플라스크웍스, 엘엘씨 세포 배양을 위한 시스템 및 방법
CN113584116A (zh) * 2021-08-19 2021-11-02 深圳科诺医学检验实验室 一种间充质干细胞免疫调控功能的检测方法
CN113877016A (zh) * 2021-10-12 2022-01-04 中南大学湘雅二医院 一种淋巴细胞分离、经干细胞免疫调控及净化回输系统

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
US4614513A (en) * 1984-08-13 1986-09-30 Fred Hutchinson Cancer Research Center Method and apparatus for treatment to remove immunoreactive substances from blood
US5753227A (en) * 1993-07-23 1998-05-19 Strahilevitz; Meir Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases
BR9712988A (pt) * 1996-10-11 2000-10-24 Univ California Imunoterapia do câncer usando células tumorais combinadas com mistura de linfócitos
DE69910362T2 (de) * 1998-04-03 2004-06-24 Osiris Therapeutics, Inc. Anwendung der mesenchymalen stammzellen als immunsuppressiva
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6680380B1 (en) * 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
US6607501B2 (en) * 2001-05-14 2003-08-19 Reynolds G. Gorsuch Process and apparatus for utilization of in vivo extracted plasma with tissue engineering devices, bioreactors, artificial organs, and cell therapy applications
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
EP1913126B1 (en) * 2005-08-12 2019-09-25 Clemson University Research Foundation Co-culture bioreactor system
US9388382B2 (en) * 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
ES2452595T3 (es) * 2005-10-13 2014-04-02 Anthrogenesis Corporation Inmunomodulación usando células madre de la placenta
JP5117859B2 (ja) * 2005-10-21 2013-01-16 株式会社カネカ 幹細胞の分離材および分離方法
GB2454386B (en) * 2006-07-06 2011-07-06 Es Cell Int Pte Ltd Method for embryonic stem cell culture on a positively charged support surface
US8241621B2 (en) * 2006-12-18 2012-08-14 Medistem Laboratories Stem cell mediated treg activation/expansion for therapeutic immune modulation

Also Published As

Publication number Publication date
BR112012013780A2 (pt) 2019-09-24
ES2784183T3 (es) 2020-09-22
CA2782757A1 (en) 2011-07-21
KR101718773B1 (ko) 2017-03-22
DK2510084T3 (da) 2020-04-27
IL220290A (en) 2017-07-31
US9101726B2 (en) 2015-08-11
WO2011087637A1 (en) 2011-07-21
KR20120120988A (ko) 2012-11-02
EP2510084B1 (en) 2020-02-05
EP2510084A4 (en) 2015-04-08
CN102471753A (zh) 2012-05-23
IL220290A0 (en) 2012-07-31
US20120277652A1 (en) 2012-11-01
JP6047403B2 (ja) 2016-12-21
CN102471753B (zh) 2014-10-22
CA2782757C (en) 2017-07-18
BR112012013780B1 (pt) 2021-02-17
AU2010341703B2 (en) 2016-01-21
AU2010341703A1 (en) 2012-06-21
JP2013526839A (ja) 2013-06-27
EP2510084A1 (en) 2012-10-17

Similar Documents

Publication Publication Date Title
BR112012013780B8 (pt) biorreator para modular linfócitos e suprimir células t autorreativas, sistema para inibição de um distúrbio autoimune, e, método ativar células t reguladoras
He et al. Pathogenesis of osteoarthritis: risk factors, regulatory pathways in chondrocytes, and experimental models
Li et al. Let-7 microRNAs regenerate peripheral nerve regeneration by targeting nerve growth factor
BR112013002859A2 (pt) sistema e aparelho para tratamento de células
MX2016010923A (es) Metodo para generar celulas t compatibles para el trasplante alogenico.
SG10201903822XA (en) Method for the enrichment of circulating tumor dna
Shi et al. Evidence of the role of R-Spondin 1 and its receptor Lgr4 in the transmission of mechanical stimuli to biological signals for bone formation
CL2007001335A1 (es) Anticuerpo anti cd40; acido nucleico que lo codifica; celula; cultivo celular; metodo de produccion; composicion farmaceutica; metodo para seleccionar un anticuerpo anti cd40; y su uso para tratar sintomas de un trastorno autoinmune y/o un trastorno inflamatorio y/o para reducir el rechazo al injerto y/o para el tratamiento de cancer positivos a cd40.
CL2011003151A1 (es) Sistema y proceso de tratamiento de aguas residuales que comprende 1ra zona de reacción biológica (i) y una 2da zona de reacción biológica (ii) que comprende un subsistema de separación para mantener un adsorbente en (ii), un sistema de suspension para suspender el adsorbente en (ii), y un sistema de operación de membrana.
MX350372B (es) Metodo para posicionar un miembro de formacion de luz.
MX2021015653A (es) Sistemas de tratamiento de fluidos biologicos.
DK1590467T3 (da) Anvendelse af regulatoriske sekvenser til specifik, transient ekspression i neuronalt bestemte celler
Kim et al. Dynamic regulation of miRNA expression by functionally enhanced placental mesenchymal stem cells promoteshepatic regeneration in a rat model with bile duct ligation
Ren et al. The activation of protein homeostasis protective mechanisms perhaps is not responsible for lifespan extension caused by deficiencies of mitochondrial proteins in C. elegans
MX2016002584A (es) Metodo para mejorar la biocompatibilidad de una superficie.
Kim et al. Density-dependent differentiation of tonsil-derived mesenchymal stem cells into parathyroid-hormone-releasing cells
Nagaraj et al. Complement inhibitor CD55 governs the integrity of membrane rafts in pancreatic beta cells, but plays no role in insulin secretion
Park et al. Tensin Regulates Fundamental Biological Processes by Interacting with Integrins of Tonsil-Derived Mesenchymal Stem Cells
Zubković et al. The virus-induced upregulation of the miR-183/96/182 cluster and the FoxO family protein members are not required for efficient replication of HSV-1
Sriha et al. BET and CDK inhibition reveal differences in the proliferation control of sympathetic ganglion neuroblasts and adrenal chromaffin cells
WO2012085268A3 (de) Zellreaktor
BR112014000044B8 (pt) Anticorpos monoclonais, célula de hibridoma e composições farmacêuticas e respectivos usos
Dalmao-Fernandez et al. FRI0506 ROLE OF MITOCHONDRIA FROM PATIENTS WITH OA IN CELLULAR SENESCENCE
Lee et al. Antisense Oligonucleotides against Let-7 Enhance the Therapeutic Potential of Mesenchymal Stromal Cells
ZHANG et al. Effects from cyclic mechanical stretch on proliferation of rheumatoid arthritis fibroblast-like synoviocytes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO